NEU 1.54% $15.32 neuren pharmaceuticals limited

ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-101

  1. 635 Posts.
    lightbulb Created with Sketch. 436
    A single drug and multiple study failures leave Anavex with nothing but cash

    By Adam Feuerstein Jan. 2, 2024

    It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$15.32
Change
-0.240(1.54%)
Mkt cap ! $1.958B
Open High Low Value Volume
$15.61 $15.93 $14.96 $8.851M 580.8K

Buyers (Bids)

No. Vol. Price($)
2 6444 $15.18
 

Sellers (Offers)

Price($) Vol. No.
$15.33 2341 1
View Market Depth
Last trade - 16.10pm 20/08/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.